CEBPA and acute myeloid leukemia: investigated 522 newly diagnosed AML patients, 20 of whom harboring IKZF1 mutations with a significant co-occurrence of mutations in SF3B1, CSF3R, and CEBPA. The authors describe a significantly reduced CR rate for patients with IKZF1 mutations (62).